The short answer
Kava may add to drowsiness from azelastine nasal spray. Eye drops have much lower measured systemic exposure, so the nasal precaution should not automatically be applied to ophthalmic use.
What this answer covers
Piper methysticum preparations; extract, beverage and dose vary. Nasal and ophthalmic medication routes adjudicated separately.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- azelastine
The medicine can affect alertness
Nasal spray may cause somnolence; avoid concurrent CNS depressants because alertness can decrease further. These medication warnings do not supply a supplement-specific adverse-event rate.
What the supplement evidence shows
A small driving-simulator crossover found no significant impairment after one medicinal kava dose. Kava and oxazepam were taken in separate sessions. That null result does not establish safety of simultaneous co-use or stronger extracts.
The eye-drop formulation is different
The ophthalmic label reports plasma concentrations generally 0.02–0.25 ng/mL after 56 days of treatment. These low measured levels are distinct from the nasal exposure and do not establish an identical systemic interaction. No exact eye-drop combination study was identified.
Apply the advice to the correct route
Tell the pharmacist whether you use nasal spray or eye drops. Nasal labeling directs avoiding other CNS depressants; review the exact supplement before co-use. No protective timing gap was established, and you should not drive while impaired.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-alertness concern for nasal azelastine with sedating preparations. Low ophthalmic exposure does not justify automatic transfer of nasal warning; no exact pair rate or protective interval.
- Exact scope
- Piper methysticum preparations; extract, beverage and dose vary. Nasal and ophthalmic medication routes adjudicated separately. with Azelastine hydrochloride nasal spray; ophthalmic drops considered separately.
- Medication form and route
- intranasal medication; ophthalmic medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed azelastine
Nasal spray may cause somnolence; avoid concurrent CNS depressants because alertness can decrease further.
How this applies: Exact azelastine RxCUI 18603 IN, with stated salt/formulation/route bridge.
No exact supplement-combination incidence or validated protective spacing; salt, route and release form limits apply.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed azelastine
Ophthalmic0.05% azelastine hydrochloride: measured plasma concentrations generally 0.02–0.25 ng/mL after 56 days of eye-drop treatment. Not the nasal CNS-depressant avoidance instruction.
How this applies: Exact azelastine RxCUI 18603 IN, with stated salt/formulation/route bridge.
Same active ingredient, different formulation or combination. Product-specific results cannot be transferred as identical exposure.
Source 3: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
Advises against combining kava with other sedating substances. Products vary and separate liver-injury concerns are described.
How this applies: Interpreted for azelastine only within the stated exact preparation and endpoint limits.
No exact azelastine combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.
Source 4: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twenty-two adults in a crossover driving-simulator trial.
Kava did not significantly impair driving compared with placebo; oxazepam impaired selected measures.
How this applies: Interpreted for azelastine only within the stated exact preparation and endpoint limits.
No exact azelastine combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact azelastine article with formulation-specific evidence and uncertainty. |
Article revision: b41ca2ac0efc54fd
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.